Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF Nov. 9, 2012, issue | Archived Issues

FDA conducting ongoing safety review of Mirapex

Pharmacy focus

The U.S. Food and Drug Administration is alerting healthcare professionals about a possible increased risk of heart failure with Mirapex (pramipexole), which is used to treat the signs and symptoms of Parkinson’s disease.

» Read more


Meetings and events


Grand rounds

Click here to view upcoming grand rounds.


Upcoming CME conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - November 2012 (PDF)

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

FDA conducting ongoing safety review of Mirapex

Pharmacy focus

The U.S. Food and Drug Administration is notifying healthcare professionals about a possible increased risk of heart failure with Mirapex (pramipexole).

Results of recent studies suggest a potential risk of heart failure that needs further review of available data. Because of the study limitations, the FDA is not able to determine whether Mirapex increases the risk of heart failure. The agency is continuing to work with the manufacturer to clarify further the risk of heart failure with Mirapex and will update the public when more information is available.

Mirapex (pramipexole) is a prescription medicine used to treat the signs and symptoms of Parkinson's disease and moderate to severe symptoms of primary restless leg syndrome, in a class of medicines called dopamine agonists.

The FDA is recommending that healthcare professionals continue to follow the recommendations in the drug label when prescribing Mirapex. Patients should continue to take their Mirapex as directed and should contact their healthcare professional if they have any questions or concerns.

Click here to read the MedWatch safety alert and see a link to the FDA Drug Safety Communication.

Pharmacy and Therapeutics Committee approvals

Cedars-Sinai's P&T Committee released approvals from a recent meeting. Please see the following PDF: Pharmacy and Therapeutics Committee Approvals - August 2012 (PDF)